3.91
0.07 (1.82%)
| Previous Close | 3.84 |
| Open | 3.87 |
| Volume | 765,022 |
| Avg. Volume (3M) | 650,857 |
| Market Cap | 291,663,328 |
| Price / Earnings (TTM) | 26.07 |
| Price / Sales | 1.29 |
| Price / Book | 0.680 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Profit Margin | 5.07% |
| Operating Margin (TTM) | -14.15% |
| Diluted EPS (TTM) | 0.150 |
| Quarterly Revenue Growth (YOY) | -55.20% |
| Total Debt/Equity (MRQ) | 2.61% |
| Current Ratio (MRQ) | 12.60 |
| Operating Cash Flow (TTM) | 68.63 M |
| Levered Free Cash Flow (TTM) | 63.77 M |
| Return on Assets (TTM) | 0.71% |
| Return on Equity (TTM) | 2.74% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | OraSure Technologies, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -1.63 |
|
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Core |
| % Held by Insiders | 3.05% |
| % Held by Institutions | 91.53% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Dec 2024 | Announcement | OraSure Technologies Acquires Sherlock Biosciences |
| 02 Dec 2024 | Announcement | OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test |
| 18 Nov 2024 | Announcement | OraSure to Participate in Upcoming Investor Conference |
| 06 Nov 2024 | Announcement | OraSure Reports Q3 ’24 Revenue of $39.9 Million |
| 22 Oct 2024 | Announcement | OraSure to Announce Third Quarter 2024 Financial Results and Host Earnings Call on November 6th |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |